microRNA-targeting antisense oligonucleotide therapy (Rosetta/Regulus)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NamemicroRNA-targeting antisense oligonucleotide therapy (Rosetta/Regulus)
Drug Alias NamemicroRNA-targeting antisense therapy (Rosetta/Isis)anti-miR-191 antisense oligonucleotides (Rosetta/Regulus)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > microRNASmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionAntisense oligonucleotide inhibitors
TargetsUpdating
Therapy Area/IndicationsLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRosetta Genomics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRegulus Therapeutics IncRosetta GenomicsIonis Pharmaceuticals Inc +[4] 
Active IndicationsN/A
Inactive IndicationsLiver Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A